Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
暂无分享,去创建一个
Derrick W. Crook | Mark A. Miller | T. Louie | D. Crook | S. Gorbach | O. Cornely | Oliver A. Cornely | Thomas J. Louie | Sherwood L. Gorbach
[1] L. Brandt,et al. Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy: A Case Series of 12 Patients , 2010, Journal of clinical gastroenterology.
[2] J. Pépin,et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] D. Gerding,et al. In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 , 2007, Antimicrobial Agents and Chemotherapy.
[4] D. Gerding,et al. Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile , 2008, Antimicrobial Agents and Chemotherapy.
[5] Mark A. Miller. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection , 2010, Expert opinion on pharmacotherapy.
[6] D. Gerding,et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Jane W. Marsh,et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Stuart Johnson. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.
[9] Dhara Shah,et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance , 2010, Expert review of anti-infective therapy.
[10] C. Donskey,et al. Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease , 2008, Antimicrobial Agents and Chemotherapy.
[11] A. Kumar. Fidaxomicin versus Vancomycin for Clostridium difficile Infection , 2012 .
[12] S. Routhier,et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] I. Poxton. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. , 2010, Future microbiology.
[14] J. Bakken,et al. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] F. Barbut,et al. Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.
[16] T. Louie,et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. , 2010, Microbiology.
[17] J. V. van Dissel,et al. Clostridium difficile: controversies and approaches to management , 2009, Current opinion in infectious diseases.
[18] M. Wilcox,et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. , 2009, The Journal of antimicrobial chemotherapy.
[19] K. Wilson. The microecology of Clostridium difficile. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] T. Louie,et al. OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection , 2008, Antimicrobial Agents and Chemotherapy.
[21] R. Nelson,et al. Probiotics for treatment of Clostridium difficile-associated colitis in adults. , 2008, The Cochrane database of systematic reviews.
[22] Mark A. Miller,et al. Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] E. Kuijper,et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] E. van Nood,et al. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[25] Linda M. Spooner,et al. Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection , 2010, The Annals of pharmacotherapy.
[26] C. Kelly,et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.
[27] L. Peterson,et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. , 1989, The Journal of infectious diseases.
[28] Guang-xi Li,et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .
[29] M. Wilcox,et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. , 2007, The Journal of antimicrobial chemotherapy.
[30] D. Antonopoulos,et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.